Recombinant Human Thrombopoietin Promotes Platelet Engraftment and Improves Prognosis of Patients with Myelodysplastic Syndromes and Aplastic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation
- PMID: 28642072
- DOI: 10.1016/j.bbmt.2017.06.010
Recombinant Human Thrombopoietin Promotes Platelet Engraftment and Improves Prognosis of Patients with Myelodysplastic Syndromes and Aplastic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation
Abstract
Poor platelet graft function (PPGF) is a significant complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, no optimal treatment has been recommended. This study investigated aspects of platelet recovery after allo-HSCT, including prognostic value and the effect of recombinant human thrombopoietin (rhTPO). We retrospectively analyzed 275 patients who received allo-HSCT in our center. Of them, 135 (49.1%) patients had good platelet graft function (GPGF) and 140 (50.9%) had PPGF. The latter included 59 (21.5%) patients with primary PPGF and 81 (29.4%) with secondary PPGF. Multivariate analysis showed that male gender (P = .024), lower CD34+ cell count (P = .04), and no use of rhTPO (P <.001) were associated with PPGF. The 3-year overall survival rate of patients with PPGF (58%) was significantly less than that of patients with GPGF (82%; P <.001). We further analyzed the effect of rhTPO on prognosis of patients after allo-HSCT. Although no advantage was apparent when analyzing the entire cohort, for patients with myelodysplastic syndromes and aplastic anemia, rhTPO was associated with a significant survival advantage (P = .014).
Keywords: Platelet graft function; Prognosis; Recombinant human thrombopoietin; Stem cell transplantation.
Copyright © 2017 The American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
Similar articles
-
[Impact on platelet recovery of recombinant human thrombopoietin in severe aplastic anemia patients with allogeneic hematopoietic stem cell transplantation].Zhonghua Xue Ye Xue Za Zhi. 2018 Mar 14;39(3):207-211. doi: 10.3760/cma.j.issn.0253-2727.2018.03.007. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 29562465 Free PMC article. Chinese.
-
Recombinant Human Thrombopoietin Promotes Platelet Engraftment in Severe Aplastic Anemia Patients Following Treatment With Haploid Hematopoietic Stem Cell Transplantation using Modified Post-Transplantation Cyclophosphamide.Transplant Cell Ther. 2024 May;30(5):500-509. doi: 10.1016/j.jtct.2024.02.023. Epub 2024 Mar 4. Transplant Cell Ther. 2024. PMID: 38447750
-
Recombinant human thrombopoietin promotes platelet engraftment after haploidentical hematopoietic stem cell transplantation: a prospective randomized controlled trial.Ann Hematol. 2015 Jan;94(1):117-28. doi: 10.1007/s00277-014-2158-1. Epub 2014 Jul 30. Ann Hematol. 2015. PMID: 25069650 Clinical Trial.
-
[Clinical use of recombinant human thrombopoietin. Status and perspectives].Ugeskr Laeger. 2001 May 7;163(19):2659-62. Ugeskr Laeger. 2001. PMID: 11360368 Review. Danish.
-
Timing of allogeneic stem cell transplantation for myelodysplastic syndromes and aplastic anemia.Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):77-81. doi: 10.1182/asheducation-2014.1.77. Epub 2014 Nov 18. Hematology Am Soc Hematol Educ Program. 2014. PMID: 25696838 Review.
Cited by
-
Recombinant human thrombopoietin promotes platelet engraftment after umbilical cord blood transplantation.Blood Adv. 2020 Aug 25;4(16):3829-3839. doi: 10.1182/bloodadvances.2020002257. Blood Adv. 2020. PMID: 32790845 Free PMC article. Clinical Trial.
-
Avatrombopag for the treatment of thrombocytopenia post hematopoietic stem-cell transplantation.Ther Adv Hematol. 2022 Sep 28;13:20406207221127532. doi: 10.1177/20406207221127532. eCollection 2022. Ther Adv Hematol. 2022. PMID: 36185780 Free PMC article.
-
[Clinical analysis of bronchiolitis obliterans syndrome after haplo- hematopoietic stem cell transplantation].Zhonghua Xue Ye Xue Za Zhi. 2019 May 14;40(5):404-410. doi: 10.3760/cma.j.issn.0253-2727.2019.05.011. Zhonghua Xue Ye Xue Za Zhi. 2019. PMID: 31207706 Free PMC article. Chinese.
-
[Chinese expert consensus on the management of hemorrhagic complications after hematopoietic stem cell transplantation(2021)].Zhonghua Xue Ye Xue Za Zhi. 2021 Apr 14;42(4):276-280. doi: 10.3760/cma.j.issn.0253-2727.2021.04.002. Zhonghua Xue Ye Xue Za Zhi. 2021. PMID: 33979970 Free PMC article. Chinese. No abstract available.
-
[Impact on platelet recovery of recombinant human thrombopoietin in severe aplastic anemia patients with allogeneic hematopoietic stem cell transplantation].Zhonghua Xue Ye Xue Za Zhi. 2018 Mar 14;39(3):207-211. doi: 10.3760/cma.j.issn.0253-2727.2018.03.007. Zhonghua Xue Ye Xue Za Zhi. 2018. PMID: 29562465 Free PMC article. Chinese.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical